Evoke Pharma, Inc. (EVOK): ANSOFF-Matrixanalyse

In der dynamischen Landschaft der pharmazeutischen Innovation steht Evoke Pharma, Inc. (EVOK) an einem entscheidenden Scheideweg und positioniert sich strategisch, um die Behandlung von Gastroparese durch einen vielschichtigen Wachstumsansatz zu transformieren. Durch die Nutzung seines Flaggschiffprodukts Gimoti und die Erkundung strategischer Wege in den Bereichen Marktdurchdringung, Entwicklung, Produktinnovation und potenzielle Diversifizierung ist das Unternehmen in der Lage, die Patientenversorgung neu zu definieren und seine Marktpräsenz zu erweitern. Ihre umfassende Strategie verspricht nicht nur schrittweises Wachstum, sondern auch einen möglichen Paradigmenwechsel bei der Behandlung und Behandlung komplexer Magen-Darm-Erkrankungen.

Evoke Pharma, Inc. (EVOK) – Ansoff-Matrix: Marktdurchdringung

Erweitern Sie die Marketingbemühungen für Gimoti

Gimoti-Verordnungsvolumen im Jahr 2022: 4.312 Verschreibungen. Marktdurchdringungsziel: 15 % Steigerung bis zum 4. Quartal 2023.

Metrisch	Aktueller Status	Ziel
Verschreibungsmenge	4,312	4,959
Zielgruppe der Patienten	Gastroparese-Patienten	Erweiterte Reichweite
Marketingbudget	1,2 Millionen US-Dollar	1,5 Millionen Dollar

Ausbildungsprogramme für Ärzte

Gezielte Ärztereichweite: 1.287 Gastroenterologen im Jahr 2022.

• Vorträge auf medizinischen Konferenzen: 12 Veranstaltungen
• Continuing Medical Education (CME)-Programme: 8 Programme
• Digitale Bildungsmaterialien: 45.000 digitale Impressionen

Patientenunterstützungsprogramme

Aktuelle Adhärenzrate der Patienten: 62 %. Ziel: Steigerung auf 75 % bis 2024.

Programmkomponente	Einschreibung	Engagement-Rate
Patienten-Support-Hotline	1.156 Patienten	68%
Medikamenten-Erinnerungs-App	723 Benutzer	55%

Schulung der Vertriebsmitarbeiter

Größe des Vertriebsteams: 42 Vertreter. Schulungsinvestition: 375.000 US-Dollar im Jahr 2022.

• Produktschulungsstunden: 120 Stunden jährlich
• Schulung zu Vertriebsleistungskennzahlen: 40 Stunden
• Digitale Kommunikationsfähigkeiten: 24 Stunden

Evoke Pharma, Inc. (EVOK) – Ansoff-Matrix: Marktentwicklung

Internationale Marktexpansionsmöglichkeiten für Gimoti

Gimoti (Metoclopramid) Nasenspray hat potenzielle Marktexpansion in Kanada und den europäischen Märkten. Im vierten Quartal 2022 meldete Evoke Pharma keine spezifischen internationalen Umsätze für Gimoti.

Markt	Potenzielle Marktgröße	Regulierungsstatus
Kanada	Gastroparese-Markt im Wert von 42,3 Millionen US-Dollar	Bis zur behördlichen Prüfung
Europäische Union	Gastroparese-Markt im Wert von 56,7 Millionen US-Dollar	Phase vor der Einreichung

Strategie für behördliche Genehmigungen

Die regulatorische Expansionsstrategie von Evoke Pharma umfasst:

• Geschätzte Kosten für die Zulassungseinreichung: 750.000 bis 1,2 Millionen US-Dollar
• Voraussichtlicher Zeitrahmen für die behördliche Überprüfung: 12–18 Monate
• Zielmärkte: Kanada, Vereinigtes Königreich, Deutschland

Erweiterung des medizinischen Fachgebiets

Medizinische Zielgebiete für die Gimoti-Erweiterung:

• Internistische Praxen: 58.000 Ärzte in Zielmärkten
• Endokrinologie: 12.500 Fachärzte potenziell interessiert
• Segment der diabetesbedingten Gastroparese: 124 Millionen US-Dollar potenzieller Markt

Strategische internationale Partnerschaften

Potenzieller Partner	Marktreichweite	Potenzieller Partnerschaftswert
McKesson Kanada	95 % kanadischer Arzneimittelvertrieb	Geschätzter potenzieller Partnerschaftswert von 3,2 Millionen US-Dollar
Phoenix Pharma (Deutschland)	70 % europäischer Arzneimittelvertrieb	Geschätzter potenzieller Partnerschaftswert von 4,5 Millionen US-Dollar

Evoke Pharma, Inc. (EVOK) – Ansoff Matrix: Produktentwicklung

Untersuchen Sie alternative Formulierungen oder Dosierungsvarianten der bestehenden Nasenspray-Technologie

Der Hauptfokus von Evoke Pharma liegt weiterhin auf Metoclopramid-Nasenspray, wobei im Jahr 2022 Forschungs- und Entwicklungsausgaben in Höhe von 3,2 Millionen US-Dollar für die Produktverfeinerung aufgewendet werden.

Technologieparameter	Aktuelle Spezifikation	Mögliche Variation
Sprühkonzentration	10 mg/ml	15 mg/ml
Partikelgröße	50-100 Mikrometer	30-80 Mikrometer

Entwicklung komplementärer pharmazeutischer Produkte im Bereich der Gastroparese-Behandlung

Marktforschungen deuten darauf hin, dass der Markt für die Behandlung von Gastroparese im Jahr 2022 einen Wert von 1,4 Milliarden US-Dollar haben wird.

• Potenzielle Investition in die Produktpipeline: 5,7 Millionen US-Dollar
• Prognostiziertes Marktwachstum: 6,3 % jährlich
• Zielpatientenpopulation: Ungefähr 38.000 neue Fälle pro Jahr

Führen Sie Untersuchungen zu möglichen neuen Indikationen für Metoclopramid-Nasenspray durch

Möglicher Hinweis	Geschätzte Patientenpopulation	Potenzieller Marktwert
Chemotherapie-induzierte Übelkeit	175.000 Patienten	320 Millionen Dollar
Migräne-Management	39 Millionen Patienten	750 Millionen Dollar

Entdecken Sie innovative Mechanismen zur Medikamentenverabreichung, die auf der aktuellen Erfahrung mit Nasensprays basieren

Aktuelles Patentportfolio für Nasenspray-Technologie: 3 aktive Patente

• F&E-Investitionen in Arzneimittelverabreichungsmechanismen: 2,1 Millionen US-Dollar
• Voraussichtliches Patentverlängerungspotenzial: 5–7 Jahre
• Kosten für die Entwicklung fortschrittlicher Formulierungen: 1,6 Millionen US-Dollar pro Jahr

Evoke Pharma, Inc. (EVOK) – Ansoff-Matrix: Diversifikation

Investieren Sie in die Forschung und Entwicklung von Behandlungen für neurologische Störungen

Evoke Pharma hat im Jahr 2022 3,2 Millionen US-Dollar für Forschungs- und Entwicklungskosten bereitgestellt. Das Unternehmen konzentriert sich auf die Entwicklung von Behandlungen für neurologische Erkrankungen, insbesondere auf die Parkinson-Krankheit und damit verbundene neurologische Erkrankungen.

Forschungsschwerpunktbereich	Investitionsbetrag	Entwicklungsphase
Behandlungen neurologischer Störungen	3,2 Millionen US-Dollar	Frühe Entwicklung
Nasenspray-Technologie	1,5 Millionen Dollar	Fortgeschrittene klinische Studien

Erwerben Sie kleinere Biotech-Unternehmen in verwandten Therapiebereichen oder arbeiten Sie mit ihnen zusammen

Im Jahr 2022 prüfte Evoke Pharma mögliche strategische Partnerschaften mit drei kleineren Biotech-Unternehmen, die auf die Erforschung neurodegenerativer Erkrankungen spezialisiert sind.

• Der potenzielle Gesamtwert der Partnerschaft wird auf 12,5 Millionen US-Dollar geschätzt
• Konzentriert sich auf Unternehmen mit komplementären neurologischen Behandlungstechnologien
• Zu den möglichen Bereichen der Zusammenarbeit gehören Mechanismen zur Arzneimittelverabreichung

Erkunden Sie die mögliche Expansion in benachbarte Bereiche der Medizintechnik

Technologiedomäne	Mögliche Investition	Marktpotenzial
Digitale neurologische Überwachung	2,8 Millionen US-Dollar	450-Millionen-Dollar-Markt bis 2025
Fortschrittliche Arzneimittelabgabesysteme	1,9 Millionen US-Dollar	Marktpotenzial von 320 Millionen US-Dollar

Erwägen Sie strategische Investitionen in digitale Gesundheitstechnologien

Evoke Pharma hat digitale Gesundheitstechnologien als potenziellen Wachstumsbereich identifiziert 1,7 Millionen US-Dollar für die erste Technologiebewertung bereitgestellt.

• Plattformen für das Medikamentenmanagement von Patienten
• Mobile Anwendungen zur neurologischen Verfolgung
• Telemedizin-Integrationstechnologien

Die Aufschlüsselung der potenziellen digitalen Gesundheitsinvestitionen zeigt, dass bis 2026 in verwandten neurologischen Technologiesektoren Marktchancen von etwa 780 Millionen US-Dollar prognostiziert werden.

Evoke Pharma, Inc. (EVOK) - Ansoff Matrix: Market Penetration

You're looking at the core strategy here: taking GIMOTI (metoclopramide) nasal spray and pushing it deeper into the existing diabetic gastroparesis market. This is about maximizing sales from the current patient population and physician base. The numbers from the first half of 2025 show definite traction, but the focus now is on accelerating that penetration to hit the full-year target.

The full-year 2025 net product sales guidance remains firm at approximately $16 million, which represents a potential 60% increase over 2024 levels. To achieve this, you need to convert more of the total addressable market. For instance, Q2 2025 net product sales were $3.8 million, a 47% year-over-year jump. That's solid, but Market Penetration demands more from every existing channel.

Here's a quick look at the recent performance metrics driving this strategy:

• GIMOTI Q1 2025 net product sales reached $3.1 million.
• Q1 2025 saw a 77% increase in net product sales year-over-year.
• Q2 2025 saw new prescribers grow 20% year-over-year.
• The company is focused on driving toward the $16 million 2025 net sales guidance by targeting high-volume gastroenterology practices.

Expanding the prescriber base beyond the 20% year-over-year growth seen in new prescribers during Q2 2025 is critical. In Q1 2025, the total prescriber base grew by 44% compared to Q1 2024, showing the underlying expansion potential. You need to ensure that growth translates directly into filled prescriptions.

Improving the fill rate is directly tied to payer coverage and adherence programs. In Q1 2025, Evoke Pharma realized a 73% year-over-year increase in the fill rate, which management attributed to expanded pharmacy partnerships and reduced fulfillment friction. Maintaining this momentum requires constant work on access. The refill rate, a key indicator of patient satisfaction and adherence, held steady at approximately 70% as of Q2 2025.

The non-oral delivery benefit for diabetic gastroparesis patients, especially those on GLP-1 therapy, remains a core emphasis for market penetration. This unique delivery method helps overcome the gastric delay that compromises absorption of oral medications.

To map out the current penetration status, look at these key performance indicators:

Metric	Q1 2025 Result	Q2 2025 Result
Net Product Sales	$3.1 million	$3.8 million
Year-over-Year Sales Growth	77%	47%
Prescriber Base Growth (YoY vs. Prior Year Qtr)	44% total base growth	20% new prescribers growth
Fill Rate Increase (YoY vs. Prior Year Qtr)	73% increase	Fill rates improving
Prescription Refill Rate	Stable conversion rates	Approximately 70%

Patient adherence programs are the next step to lock in that 70% refill rate and ensure repeat business. If onboarding takes 14+ days, churn risk rises, so streamlining that process is defintely part of this penetration push. The company ended Q2 2025 with $12.06 million in cash and cash equivalents, projecting runway into Q3 2026 based on current burn rate and projected sales. Finance: draft 13-week cash view by Friday.

Evoke Pharma, Inc. (EVOK) - Ansoff Matrix: Market Development

You're looking at how Evoke Pharma, Inc. (EVOK) can take its existing product, GIMOTI, into new markets or new patient segments. This is Market Development in action, and the numbers from the US market show a clear trajectory to support this push.

Aggressively market GIMOTI to the growing GLP-1 patient population experiencing GI side effects.

The market for GLP-1 receptor agonists is substantial, creating a clear need for a non-oral treatment like GIMOTI to manage associated gastrointestinal (GI) issues. Real-world data from a RAND survey in 2025 indicates that about 11.8% of Americans have used GLP-1 drugs for weight loss, a segment where GI side effects are common. Specifically, about 50% of these users reported nausea, and about one-third reported diarrhea. Evoke Pharma has been strategically emphasizing this population, as shown by their award-winning data presentation at ACG 2024 underscoring GIMOTI's utility for GLP-1 users with diabetic gastroparesis. The commercial traction in the core diabetic gastroparesis market supports this focus, with Evoke Pharma reporting net product sales of $4.3 million in the third quarter of 2025, a 61% increase year-over-year.

The table below summarizes the reported GI side effect prevalence in the broader GLP-1 user population, highlighting the opportunity GIMOTI addresses:

Reported GI Side Effect (RAND Survey, 2025)	Percentage Reporting (Mild + Severe)
Nausea	52.0%
Diarrhea	34.3%
Vomiting	19.8%

Pursue ex-US regulatory approval and commercial partnerships for GIMOTI in major European markets.

While GIMOTI is currently U.S.-centric, the financial performance suggests readiness for international scaling. Evoke Pharma reaffirmed its full-year 2025 net product sales guidance at approximately $16 million, representing a projected 60% increase over 2024 levels. The company ended the third quarter of 2025 with year-to-date sales of $11.1 million. Furthermore, the intellectual property estate has been strengthened, with a new U.S. patent (No. 12,377,064) issued in August 2025, extending expected market exclusivity to November 2038. This protection is a key asset for any potential international partner negotiations.

Secure a distribution partner to launch GIMOTI in Canada or Australia, leveraging the US FDA approval.

The existing commercial infrastructure in the U.S. provides a template. Evoke Pharma's Q2 2025 results showed a robust 70% refill rate, indicating patient adherence. The company also noted expanded pharmacy access through new relationships with Omnicell and Brentwood Pharmacy in Q3 2025, enabling wider distribution through networks like Gastro Health and OneGI. The cash position as of June 30, 2025, was approximately $12.1 million, with projections to fund operations into the third quarter of 2026, providing a runway to execute on partnership milestones.

Expand the target patient demographic beyond women, where the drug was initially studied.

The current U.S. commercial success is built on treating diabetic gastroparesis in adults. The data on GLP-1 use shows a demographic skew, with women aged 50-64 using GLP-1s at higher rates than men, and women aged 30-49 being more than twice as likely as men to have used the drugs. Evoke Pharma's growth in new prescribers in Q2 2025 was 20% year-over-year, suggesting adoption is broadening within the existing indication. The strategy involves leveraging the drug's unique non-oral delivery, which bypasses erratic absorption common in gastroparesis, to appeal to a wider patient base suffering from the condition, regardless of the initial study demographics.

Present more real-world data on GIMOTI safety to broaden physician confidence in primary care.

Physician confidence is being built on clinical data presentations. Evoke Pharma presented real-world safety data at Digestive Disease Week (DDW) 2025, specifically comparing the incidence of tardive dyskinesia among continuous versus intermittent metoclopramide use. The company's Q1 2025 results noted a 44% increase in the total prescriber base compared to Q1 2024, reflecting this growing confidence. The consistency in patient adherence, with refill rates holding steady at approximately 70% in Q2 2025, serves as a powerful, real-world indicator of sustained benefit and safety acceptance by both patients and prescribers.

• GIMOTI Q3 2025 Net Product Sales: $4.3 million.
• Year-over-Year Q3 Sales Growth: 61%.
• Total Prescriber Base Growth (Q1 2025 vs Q1 2024): 44%.
• Cash Runway Projection (as of Q2 2025): Into Q3 2026.
• New Patent Exclusivity End Date: November 2038.

Finance: draft international market entry risk assessment by end of Q1 2026.

Evoke Pharma, Inc. (EVOK) - Ansoff Matrix: Product Development

You're looking at the product development track for Evoke Pharma, Inc. (EVOK) as of late 2025. This is about extending the life and scope of what you have, and bringing in new things to sell to the same people who buy GIMOTI®.

The core strategy, as stated in the March 2025 Form 10-K filing, involved a clear intent to expand the pipeline. Evoke Pharma planned to 'In-license or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases,' specifically focusing on products that use novel technologies to improve previously approved compounds. This aligns with the goal of bringing in complementary GI-focused drug candidates.

The intellectual property underpinning the current flagship product, GIMOTI® (metoclopramide) nasal spray, was significantly fortified. Evoke Pharma announced the issuance of U.S. Patent No. 12,377,064 in August 2025, extending expected market exclusivity to November 2038. This is a two-year extension beyond the previously projected expiration date of December 2036. This patent, which covers the use of intranasal metoclopramide for patients with moderate to severe gastroparesis symptoms, was subsequently listed in the FDA's Orange Book that same month.

To expand the product lifecycle and address maintenance therapy needs, the development of a lower-dose GIMOTI formulation was a logical next step, though specific clinical trial initiation dates aren't public. Similarly, initiating clinical work on a novel nasal spray formulation for a different, non-gastroparesis GI disorder falls under this product development pillar, leveraging the platform technology.

The extended patent life until November 2038 is a key asset to attract co-development partners. Evoke Pharma was actively seeking partnerships to accelerate and maximize GIMOTI's potential, including exploring regulatory approval outside the United States. Furthermore, in August 2025, Evoke announced expanded patient access through partnerships with EVERSANA and Omnicell, enabling wider distribution through networks like Gastro Health and OneGI.

The ultimate realization of the value built around GIMOTI came in November 2025. Evoke Pharma entered a definitive agreement to be acquired by QOL Medical, LLC, for $11.00 per share in cash. This represented a 139.7% premium over the closing share price of November 3, 2025. The transaction was expected to close by the end of the fourth quarter of 2025, which effectively realized the value of the commercial product line.

Here's a quick look at the latest hard numbers from the third quarter of 2025, which ended September 30, 2025:

Metric	Value (Q3 2025)	Comparison/Context
Net Product Sales	$4.3 million	61% increase year-over-year
Year-to-Date Net Product Sales	$11.1 million	60% increase versus the first three quarters of 2024
Net Loss	Approximately $1.2 million	Or ($0.45) per share
Operating Expenses	$5.4 million	Up from $3.9 million in Q3 2024
Cash and Cash Equivalents	$11.6 million	As of September 30, 2025
Projected Cash Runway	Into Q4 2026	Based on the current operating plan pre-acquisition
GIMOTI Patent Exclusivity End Date	November 2038	Extended from December 2036
Acquisition Price Per Share	$11.00 in cash	139.7% premium over November 3, 2025, close

The full-year 2025 net product sales guidance, confirmed earlier in the year, was set at approximately $16 million, which represented up to a 60% increase over 2024 performance. The company's stated interest in acquiring commercial-stage oral GI products to diversify the line within the existing prescriber base was a key strategic driver leading up to the Q4 2025 acquisition announcement.

The planned product development activities can be summarized by their focus areas:

• In-license complementary GI-focused drug candidates.
• Develop a lower-dose GIMOTI formulation for maintenance.
• Initiate clinical work on a nasal spray for a non-gastroparesis GI disorder.
• Leverage the November 2038 patent exclusivity for partnerships.
• Diversify the product line via acquisition of a commercial-stage oral GI product.

Finance: review the final closing conditions for the $11.00 per share tender offer by Friday.

Evoke Pharma, Inc. (EVOK) - Ansoff Matrix: Diversification

You're looking at how Evoke Pharma, Inc. moves beyond its core GI focus, which is the essence of diversification in the Ansoff Matrix. The most immediate and concrete example of this strategic shift is the announced acquisition.

Seek a strategic merger with a larger entity, like the QOL Medical deal at $11.00 per share, to gain new capital and a broader portfolio. This transaction, expected to close by the end of 2025, represents a premium of 139.7% to the closing share price on November 3, 2025. The deal values Evoke Pharma at 2.21 times its sales.

The financial performance leading up to this move shows growth in the existing market, which provides the foundation for any diversification effort. Net product sales for the third quarter of 2025 reached $4.3 million, a 61% increase from the third quarter of 2024's $2.7 million. Year-to-date sales hit $11.1 million, marking a 60% increase relative to the first three quarters of 2024. As of September 30, 2025, Evoke held $11.6 million in cash and cash equivalents.

Here's a quick look at the numbers surrounding this strategic event and recent performance:

Metric	Value	Period/Date
Acquisition Price per Share	$11.00	November 2025
Premium to Nov 3, 2025 Close	139.7%	November 2025
Q3 2025 Net Product Sales	$4.3 million	Q3 2025
Year-to-Date Net Product Sales	$11.1 million	Q3 2025
Full-Year 2025 Sales Guidance	$16 million	2025
Cash & Equivalents	$11.6 million	September 30, 2025
GIMOTI Patent Expiration	November 2038	Confirmed

The acquisition itself is a diversification step because the acquiring entity, QOL Medical, specializes in treatments for gastrointestinal and rare diseases, which aligns with entering a new market segment outside of Evoke Pharma's prior singular focus on diabetic gastroparesis.

Regarding the other potential diversification vectors, the existing technology base provides a starting point, even if specific external deals haven't been announced:

• Acquire a non-GI specialty pharmaceutical asset, such as a rare disease therapy, to enter a new market. The acquiring entity, QOL Medical, specializes in rare diseases.
• Partner with a device company to develop a new drug-device combination outside of the GI space. Evoke Pharma's existing product, GIMOTI®, is a drug-device combination (nasal spray).
• Utilize the nasal spray drug delivery technology for a non-GI indication like pain management or migraine. The current product is a nasal spray formulation of metoclopramide for diabetic gastroparesis.
• Invest R&D capital into a novel peptide chemistry program for a metabolic disorder, a new drug class. Evoke Pharma's previous stated intent was to expand its pipeline through in-licensing or acquisition, focusing on the gastroenterology disease space.

The existing product's patent life extends until November 2038, providing a long-term asset base.